Cognition Therapeutics Q2 2026 net loss $3.9M; advances Phase 3 plan for DLB psychosis

COGNITION THERAPEUTICS INC

Net loss of $3.9M ($0.04 per share) vs $6.7M loss in Q2 2025.
R&D expenses fell to $5.1M from $11.5M; G&A $2.6M vs $2.5M.
Cash $34.8M plus $21.6M grant funds; runway into Q4 2027.
FDA meeting on Phase 3 trial for DLB psychosis; initiation planned for mid-2027.
New composition of matter patent allowed for zervimesine extending protection to 2045.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.